Hangzhou Zhongmei Huadong Pharmaceutical

Diversified pharma / peptide therapeutics

000963 · SZSE · China

Public Market Listing

000963SZSE

SZSE primary exchange listing

Live quotes, historical charts, and market capitalization for Hangzhou Zhongmei Huadong Pharmaceutical are available on Yahoo Finance.

View quote & market cap on Yahoo Finance ↗

External market data link · No third-party exchange redistribution

Assets

(7 total)
7Total Assets
0Approved
5Phase 3 / Filed
2Phase 1–2 / Early
6Diseases
Quick filter:
Showing 7 of 7 assets
Target & Modality
Phase 3
GLP-1 receptorPeptide
Type 2 Diabetes
Phase 3
GLP-1 receptorSmall molecule
ObesityType 2 Diabetes
Phase 3
GLP-1/GIP receptor (dual)Peptide
ObesityType 2 Diabetes
janagliflozin(Huiyoujing)
Phase 3
SGLT2Small molecule
Type 2 DiabetesChronic Kidney Disease
Phase 3
JAK1 · JAK1Small molecule
Atopic Dermatitis
Phase 1/2
BCMACell therapy
Multiple Myeloma
Phase 1
FGFR2bAntibody–drug conjugate
Non-Small Cell Lung Cancer

Upcoming events

(6 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (4)
February 2027 (2)
HDM1005Phase 2Obesity
Est. primary completion 2027-02-04 · NCT07521631 · CT.gov ↗
What to watch
HDM1002Phase 3Type 2 Diabetes
Est. primary completion 2027-02-16 · NCT07082114 · CT.gov ↗
What to watch
August 2027 (2)
HDM1005Phase 3Type 2 Diabetes
Est. primary completion 2027-08-28 · NCT07394114 · CT.gov ↗
What to watch
HDM1005Phase 3Type 2 Diabetes
Est. primary completion 2027-08-30 · NCT07417306 · CT.gov ↗
What to watch
2028 (2)
March 2028 (1)
HDM1005Phase 3Obstructive Sleep Apnea (OSA) and Obesity
Est. primary completion 2028-03 · NCT07787260 · CT.gov ↗
What to watch
September 2028 (1)
HDM1005Phase 3Obstructive Sleep Apnea (OSA) and Obesity
Est. primary completion 2028-09 · NCT07794397 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(2)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

27 September 2026Topline resultHDM1002HDM1002-301 Phase 3 in China met all primary and key secondary endpoints at week 44
CN · Huadong Medicine · Source ↗
31 March 2025Filing acceptedHDG1901NMPA accepts China marketing application for semaglutide injection (HDG1901) in type 2 diabetes
China, NMPA · Hangzhou Zhongmei Huadong Pharmaceutical Jiangdong Co., Ltd. (wholly owned subsidiary of Huadong Medicine) · Source ↗

Financial reports

Quarterly & interim (1)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-Q3——$615M—report ↗

Hangzhou Zhongmei Huadong Pharmaceutical reported cash and equivalents of $614.64M for Q3 2025.

Figures only: this period's report disclosed no narrative text

Annual history (1 year)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$6.1B$244M——report ↗